When it comes to “bad” cholesterol, most cardiologists say lower is better. But what’s the best way to get that number down?

Scribe expects to initiate a first-in-human hypercholesterolemia study in mid-2026 with STX-1150, its lead cardiometabolic assetSTX-1150 is designed to deliver durable therapeutic LDL-C lowering with ...

He Jiankui’s name became synonymous with scientific transgression when his secret experiment produced the world’s first ...

NHS Scotland has approved a one-time CRISPR gene therapy for severe sickle cell disease, offering durable reduction in ...

Parse Biosciences and Graph Therapeutics (Graph) today announced a strategic partnership to create one of the largest and most comprehensive immune cell perturbation atlases. The collaboration will ...

People Science, a leader in decentralized clinical research, today announced the publication of a clinical study conducted with Verb Biotics in Nature Scientific Reports. The peer-reviewed trial ...

Inaugural event takes place from 9–10 March at Hinxton Hall in Cambridge, UKProgramme spans neurological disorders, sensory ...

Cathie Wood predicts stock market golden age through 2026 with 6-8% GDP growth. ARK Innovation ETF returned 35% in 2025 vs ...

Cancer drugs are always popular biotech investments, but autoimmune disease also figures prominently in the startup ...

Neurodegenerative diseases (NDDs) represent a profound challenge to global health, characterized by progressive neuronal dysfunction and loss, leading to ...

Fledgling universities funded by kings and other leaders hired professors for their chemistry departments. Organic chemistry ...

The deletion of two cancer genes, CHD1 and MAP3K7, improves how well tumors respond to cancer immunotherapy and could be used ...